NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.46 per share a year ago.
NovoCure: There Is Still More Upside
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment which resulted in positive price action. The lung cancer market will significanly increase Novocure's scale, on top of a strong core business that has beat growth expectations. With downside risks limited to execution or FDA recall, and a price target of $35.10, I raise my rating from buy to strong buy.
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
On Tuesday, the FDA approved NovoCure's NVCR Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why NovoCure Stock Dived by 13% This Week
The commercial-stage biotech's leader is stepping down. This change is effective on Jan. 1, 2025.
Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NovoCure Limited: A Post Q2 Analysis
Today, we take a look at NovoCure Limited, which develops and manufactures tumor treating fields devices for solid tumor cancers. The company has beat expectations for both its first and second quarter results in 2024 and is pushing to garner approval for additional indications. An analysis of NovoCure following its better than expected performance Q2 results Thursday follows in the paragraphs below.
NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript
NovoCure Limited [NVCR] Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Ingrid Goldberg - Investor Relations Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Larry Biegelsen - Wells Fargo Jessica Fye - J.P. Morgan Vijay Kumar - Evercore ISI Emily Bodnar - H.C.
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago.
